

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:36:12 ON 17 AUG 2006

=> d his ful

FILE 'HCAPLUS' ENTERED AT 10:37:51 ON 17 AUG 2006

L1 1 SEA ABB=ON US20050014220/PN
SEL RN

FILE 'REGISTRY' ENTERED AT 10:39:10 ON 17 AUG 2006

L2 17 SEA ABB=ON (477950-55-3/BI OR 477950-56-4/BI OR
477950-57-5/BI OR 477950-58-6/BI OR 477991-18-7/BI OR
477991-19-8/BI OR 477991-20-1/BI OR 477991-21-2/BI OR
477994-28-8/BI OR 477994-29-9/BI OR 477994-30-2/BI OR
477994-31-3/BI OR 477994-32-4/BI OR 477994-33-5/BI OR
477994-34-6/BI OR 477994-35-7/BI OR 60202-16-6/BI)
L3 STR
L4 45 SEA SSS SAM L3
L5 STR L3
L6 5 SEA SSS SAM L5
L7 844 SEA SSS FUL L3
L8 5 SEA SUB=L7 SSS SAM L5
L9 0 SEA ABB=ON L7 AND L2
L10 39 SEA SUB=L7 SSS FUL L5
SAV L7 HEA360/A
SAV L10 HEA360A/A

FILE 'HCAPLUS' ENTERED AT 11:45:46 ON 17 AUG 2006


L11 19 SEA ABB=ON L10
L12 308 SEA ABB=ON L7
L13 289 SEA ABB=ON L12 NOT L11
L14 1 SEA ABB=ON US20050004009/PN
SEL RN

FILE 'REGISTRY' ENTERED AT 12:46:12 ON 17 AUG 2006

L15 28 SEA ABB=ON (286465-43-8/BI OR 286465-44-9/BI OR
400628-17-3/BI OR 725233-52-3/BI OR 725233-53-4/BI OR
725233-54-5/BI OR 725233-55-6/BI OR 725233-56-7/BI OR
725233-57-8/BI OR 725233-59-0/BI OR 725233-60-3/BI OR
725233-61-4/BI OR 725233-62-5/BI OR 725233-63-6/BI OR
725233-64-7/BI OR 725233-65-8/BI OR 725233-66-9/BI OR
725233-67-0/BI OR 725233-68-1/BI OR 751481-25-1/BI OR
751481-26-2/BI OR 751481-27-3/BI OR 751481-28-4/BI OR
752718-90-4/BI OR 752718-91-5/BI OR 752718-92-6/BI OR
752718-93-7/BI OR 752718-94-8/BI)
L16 22 SEA ABB=ON L7 AND L15
L17 6 SEA ABB=ON L15 NOT L16

FILE 'HCAPLUS' ENTERED AT 12:47:01 ON 17 AUG 2006

L18 6 SEA ABB=ON L16
L19 19 SEA ABB=ON L18 OR L11
L20 73 SEA ABB=ON L13 AND PHARM?/SC,SX
L21 5 SEA ABB=ON L20 AND PEPTIDOMIMET?
L22 12 SEA ABB=ON L13 AND PEPTIDOMIMET?
L23 12 SEA ABB=ON L21 OR L22
L24 7 SEA ABB=ON L13 AND ?INFLAMM?
L25 19 SEA ABB=ON L23 OR L24
L26 797385 SEA ABB=ON CANCER? OR CARCINOMA? OR MELANOMA? OR
NEOPLAS? OR ?TUMOR? OR ?TUMOUR? OR MALIGNAN?
L27 20 SEA ABB=ON L20 AND L26



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L7 844 SEA FILE=REGISTRY SSS FUL L3

L10 39 SEA FILE=REGISTRY SUB=L7 SSS FUL L5

L11 19 SEA FILE=HCAPLUS ABB=ON L10

=> d que 128

L3 STR

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L5 STR

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L7 844 SEA FILE=REGISTRY SSS FUL L3
L10 39 SEA FILE=REGISTRY SUB=L7 SSS FUL L5
L11 19 SEA FILE=HCAPLUS ABB=ON L10
L12 308 SEA FILE=HCAPLUS ABB=ON L7
L13 289 SEA FILE=HCAPLUS ABB=ON L12 NOT L11
L20 73 SEA FILE=HCAPLUS ABB=ON L13 AND PHARM?/SC,SX
L21 5 SEA FILE=HCAPLUS ABB=ON L20 AND PEPTIDOMIMET?
L22 12 SEA FILE=HCAPLUS ABB=ON L13 AND PEPTIDOMIMET?
L23 12 SEA FILE=HCAPLUS ABB=ON L21 OR L22
L24 7 SEA FILE=HCAPLUS ABB=ON L13 AND ?INFLAMM?
L25 19 SEA FILE=HCAPLUS ABB=ON L23 OR L24
L26 797385 SEA FILE=HCAPLUS ABB=ON CANCER? OR CARCINOMA? OR
MELANOMA? OR NEOPLAS? OR ?TUMOR? OR ?TUMOUR? OR
MALIGNAN?
L27 20 SEA FILE=HCAPLUS ABB=ON L20 AND L26
L28 32 SEA FILE=HCAPLUS ABB=ON L25 OR L27

=> fil hcap
FILE 'HCAPLUS' ENTERED AT 12:36:32 ON 17 AUG 2006

=> d l11 1-19 ibib abs hitstr hitind

L11 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:307869 HCAPLUS
DOCUMENT NUMBER: 145:483
TITLE: Selective Inhibition of ErbB2-Overexpressing
Breast Cancer In vivo by a Novel TAT-Based
ErbB2-Targeting Signal Transducers and
Activators of Transcription 3 Blocking Peptide
AUTHOR(S): Tan, Ming; Lan, Keng-Hsueh; Yao, Jun; Lu,
Chien-Hsing; Sun, Menghong; Neal, Christopher
L.; Lu, Jing; Yu, Dihua
CORPORATE SOURCE: Departments of Surgical Oncology and Molecular
and Cellular Oncology, The University of Texas
M.D. Anderson Cancer Center, Houston, TX,
77030, USA
SOURCE: Cancer Research (2006), 66(7), 3764-3772
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB ErbB2 is an excellent target for cancer therapies. Unfortunately,
the outcome of current therapies for ErbB2-pos. breast cancers
remains unsatisfying due to resistance and side effects. New
therapies for ErbB2-overexpressing breast cancers continue to be
in great need. Peptide therapy using cell-penetrating peptides
(CPP) as peptide carriers is promising because the internalization
is highly efficient, and the cargoes delivered can be bioactive.
However, the major obstacle in using these powerful CPPs for
therapy is their lack of specificity. Here, we sought to develop
a peptide carrier that could introduce therapeutics specifically
to ErbB2-overexpressing breast cancer cells. By modifying the HIV
TAT-derived CPP and conjugating anti-HER-2/neu peptide mimetic